Together, these findings suggest that HSP90 may regulate the BCR signal in CLL cells via stabilization of multiple components of the BCR signalosome and that, CD79a, BCAP and PLCγ2 are the new addition to the growing “client-protein” list of HSP90. The gene discussed is PLCG2; the disease is B-cell chronic lymphocytic leukemia.